Mechanical Ventilation and the Titer of Antibodies as Risk Factors for the Development of Transfusion-Related Lung Injury by Vlaar, A. P. J. et al.
Hindawi Publishing Corporation
Critical Care Research and Practice
Volume 2012, Article ID 720950, 7 pages
doi:10.1155/2012/720950
Research Article
MechanicalVentilationandtheTiterofAntibodiesasRiskFactors
fortheDevelopmentof Transfusion-RelatedLung Injury
A.P. J. Vlaar,1,2 M.T. Kuipers,1,2 J. J. Hofstra,2,3 E.K. Wolthuis,2,3 C.W.Wieland,2
J. J. T. H. Roelofs,4 L.Boon,5 M. J. Schultz,1,2 R. Lutter,6 and N. P. Juffermans1,2
1Department of Intensive Care Medicine, Academic Medical Center, 1105 AZ Amsterdam, The Netherlands
2Laboratory of Experimental Intensive Care and Anesthesiology (LEICA), Academic Medical Center,
1105 AZ Amsterdam, The Netherlands
3Department of Anesthesiology, Academic Medical Center, 1105 AZ Amsterdam, The Netherlands
4Department of Pathology, Academic Medical Center, 1105 AZ Amsterdam, The Netherlands
5Bioceros B.V., 3584 CM Utrecht, The Netherlands
6Departments of Respiratory Medicine and Experimental Immunology, Academic Medical Center,
1105 AZ Amsterdam, The Netherlands
C o r r e s p o n d e n c es h o u l db ea d d r e s s e dt oA .P .J .V l a a r ,a.p.vlaar@amc.uva.nl
Received 13 February 2012; Accepted 5 April 2012
Academic Editor: Mark T. Keegan
Copyright © 2012 A. P. J. Vlaar et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Purpose.Onsetoftransfusion-relatedacutelunginjury(TRALI)issuggestedtobeathreshold-event.Dataislackingontherelation
betweentiterofantibodiesinfusedandonsetofTRALI.WedeterminedwhetheronsetofTRALIisdependentonthetiterofMHC-
I antibodies infused in a combined model of ventilator-induced lung injury and antibody-induced TRALl. Methods. BALB/c mice
were ventilated for ﬁve hours with low (7.5ml/kg) or high (15ml/kg) tidal volume. After three hours of MV, TRALI was induced
by infusion of 0.5mg/kg, 2.0mg/kg or 4.5mg/kg MHC-I antibodies. Control animals received vehicle. After ﬁve hours of MV,
animals were sacriﬁced. Results. MV with high tidal volumes resulted in increased levels of all markers of lung injury compared
to animals ventilated with low tidal MV. In ventilator-induced lung injury, infusion of 4.5mg/kg of antibodies further increased
pulmonary wet-to-dry ratio, pulmonary neutrophil inﬂux and pulmonary KC levels, whereas infusion of lower dose of antibodies
did not augment lung injury. In contrast, mice ventilated with low tidal volumes did not develop lung injury, irrespective of the
dose of antibody used. Conclusions. In the presence of injurious MV, onset of TRALI depends on the titer of antibodies infused.
1.Introduction
Transfusion-related acute lung injury (TRALI) is the leading
cause of transfusion-related morbidity and mortality [1–3].
The pathogenesis of TRALI has not been fully elucidated. A
“two hit” event has been postulated [4]. The ﬁrst event is
an inﬂammatory condition of the patient (e.g., sepsis, recent
surgery) causing sequestration and priming of neutrophils
in the pulmonary compartment. The second event is the
transfusion, containing either antibodies or bioactive lipids
that have accumulated during blood storage, stimulating
the primed neutrophils to release proteases. The result is
endothelial damage, capillary leak, and extravasation of
neutrophils, ﬁnally resulting in pulmonary edema, that is,
TRALI.
The association between HLA antibodies in donor
plasma and TRALI is not always apparent [5–7]. A threshold
model has been suggested [8], in which a threshold must be
overcometoinduceaTRALIreaction.Factorsthatdetermine
the threshold are the predisposition of the patient that
determines priming of the lung neutrophils and the ability
of the mediators in the transfusion to cause activation of
primed neutrophils. A strong antibody-mediated response
can cause severe TRALI in an otherwise “healthy” recipient.
When activation status is too low, it is possible that priming
factors in the transfusion are not strong enough to overcome
the threshold. The threshold model may explain why the
estimated incidence of TRALI is higher in cardiac surgery
and critically ill patients [9–12]. These patients often suﬀer
from an inﬂammatory condition, which may contribute to2 Critical Care Research and Practice
neutrophil priming, after which transfusion of mediators
with low activating capacity may be suﬃcient to overcome
the threshold to induce a TRALI reaction [11]. Indeed, LPS
priming allowed for lower amounts of antibody needed to
induce TRALI [13]. In line with this, sepsis was found to
be a risk factor for TRALI in critically ill patients [9, 11].
In addition, we recently showed that mechanical ventilation
(MV) aggravates the course of a TRALI reaction in a murine
model [14]. Although data on patient-related risk factors
is increasing [9–11, 15], data on the threshold titer of
antibodies needed to induce TRALI is sparse.
Blood transfusion signiﬁcantly contributes to morbidity
and mortality in trauma, general surgery, and critically ill
patients [16]. Understanding the interaction between the
underlying condition of the patient and the concentration
of antibodies needed to cause TRALI may help deﬁne
interventions that diminish the risk of TRALI. To investigate
whether onset of TRALI depends on the titer of MHC-I
antibodies infused, we tested three concentrations of MHC-I
antibodies in a combined model of TRALI and ventilator-
induced lung injury [17, 18].
2.MaterialsandMethods
The study was approved by the Animal Care And Use
Committee oftheAcademicMedicalCenter attheUniversity
of Amsterdam, Amsterdam, The Netherlands. Animal proce-
dures were carried out in compliance with the Institutional
Standards for Human Care and Use of Laboratory Animals.
2.1. MHC I mAb Production. A hybridoma (34-1-2S) was
purchased from the American Type Culture Collection that
producesamAbagainstH2Kd (IgG2a,κ).Thehybridomawas
grown in tissue culture medium containing 1% fetal bovine
serum and incubated at 37◦C and 5% CO2.H y b r i d o m a
supernatant was collected and ﬁltered through a 0.2μm
ﬁlter. The MHC I mAb was puriﬁed using protein A
Sepharoseaﬃnitychromatographyanddialyzedovernightin
PBS (pH 7.4). The protein concentration of the mAb was
spectrophotometrically determined using Bio-Rad protein
reagent.ThemAbstocksolution(2.0–2.5mg/mL)wasfrozen
at −80◦C until the time of the experiments.
2.2. Mice. Experiments were performed with healthy male
BALB/c mice (total n = 96, n = 12 per group, Charles
River, Someren, the Netherlands), aged 8 to 10 weeks, with
weights ranging from 19 to 25g. Animals were mechanically
ventilated with two diﬀerent MV strategies for 5 hours
and received 0.5, 2.0, or 4.5mg/kg MHC-I class antibodies
infusion after 3 hours of ventilation. In a previous study
using the same model, no diﬀerences between markers of
lung injury were found between animals receiving ISO-
type antibody and animals receiving vehicle infusion [14].
Therefore,onlycontrolsreceivingvehicleinfusionwereused.
2.3. Instrumentation and Anesthesia. Anesthesia was
achieved with intraperitoneal injection (i.p.) of a mix
of ketamine (Eurovet Animal Health B.V., Bladel, The
Netherlands), medetomidine (Pﬁzer Animal Health B.V.,
Capelle a/d IJssel, The Netherlands), and atropine (Phar-
machemie, Haarlem, the Netherlands) (KMA). Induction
anesthesia consisted of injection of KMA “induction”—mix:
7.5μL per gram of body weight of 1.26mL 100mg/mL
ketamine, 0.2mL 1mg/mL medetomidine, and 1mL
0.5mg/mL atropine in 5mL normal saline. Throughout the
experiments rectal temperature was maintained between
36.0 and 37.5◦C using a warming path. Maintenance
anesthesia consisted of 10μL per gram body weight of a
mix of 0.72mL 100mg/mL ketamine, 0.08mL 1mg/mL
medetomidine, and 0.3mL 0.5mg/mL atropine in 20mL
normal saline administered via an intraperitoneal catheter
(PE 10 tubing, BD, Breda, The Netherlands) every hour.
2.4. Mechanical Ventilation Strategies. A Y-tube connec-
tor, 1.0mm outer diameter and 0.6mm inner diame-
ter (VBM Medizintechnik GmbH, Sulz am Neckar, Ger-
many), was surgically inserted into the trachea under
general anesthesia. Mice were placed in a supine position
and connected to a ventilator (Servo 900 C, Siemens,
Sweden). Mice were pressure controlled ventilated with
either an inspiratory pressure of 10cm H2O (resulting in
lung-protective VT ∼ 7.5mL/kg; low VT,L V T) or an inspi-
ratory pressure of 18cm H2O (resulting in injurious VT ∼
15mL/kg; high VT,H V T). Respiratory rate was set at
110 breaths/min and 50 breaths/min with LVT and HVT,
respectively. These respiratory settings resulted in normal
PaCO2 valuesafter5hofMV[18].PEEPwassetat2cmH2O
with both MV strategies. The fraction of inspired oxygen
was kept at 0.5, and inspiration to expiration ratio was set
at 1:1. A sigh (sustained inﬂation with 30cm H2O) for 5
breaths was performed every 30 minutes. Mice received an
intraperitoneal bolus of 1mL normal saline 1 hour before
start of anesthesia and initiation of MV, followed by 0.2mL
sodium carbonate (200mmol/L NaHCO3) administered via
the intraperitoneal catheter every 30 minutes until the end
of MV. After 3 hours of MV, the jugular vein was isolated.
Using a 30-gauge sterile needle attached to PE-10 tubing,
venous blood was aspirated from the jugular vein to verify
intravascularplacementoftheneedleandtoremoveasample
of blood (∼200μL). Mice were given an i.v. volume-matched
injection (150–250μL) of either 0.5, 2.0, or 4.5mg/kg MHC-
I class antibodies. Controls received vehicle. The skin was
sutured with 6-0 silk suture, and the mice were sacriﬁced
after two more hours of MV.
2.5. Hemodynamic Monitoring. Systolic blood pressure and
heart rate were noninvasively monitored using a murine tail-
cuﬀ system (AD Instruments, Spechbach, Germany). The
data were recorded on a data acquisition system (Power-
Lab/4SP, AD Instruments). Systolic blood pressure and heart
rate were averaged from three consecutive measurements.
2.6. Study Groups and Sampling. At the end of the exper-
iment animals were sacriﬁced, and bronchoalveolar lavage
ﬂuid (BALF) was obtained from the right lung (n =
6), by instilling three times 0.5mL aliquots of saline byCritical Care Research and Practice 3
a 22-gauge Abbocath-T catheter (Abbott, Sligo, Ireland)
into the trachea. Approximately, 1.0mL of lavage ﬂuid
was retrieved per mouse, and cell counts were determined
using a hemocytometer (Beckman Coulter, Fullerton, CA,
USA). Diﬀerential counts were done (up to 100 cells per
slide) on cytospin preparations stained with a modiﬁed
Giemsa stain, Diﬀ-Quick (Dade Behring AG, D¨ udingen,
Switzerland). Supernatant was stored at −80◦C for cytokine
measurement. The left lung was weighed and dried for three
days in an oven at 65◦C. The ratio of wet weight to dry
weight represents tissue edema. Another 6 mice were used
for blood gas analysis from blood sampled from the carotid
artery. The lungs of these mice were ﬁxed in 4% formalin
and embedded in paraﬃn for histopathology. 4μms e c t i o n s
were stained with hematoxylin-eosin (H&E) and analyzed
by a pathologist who was blinded for group identity. To
score lung injury, we used a modiﬁed VILI histology scoring
systemaspreviouslydescribed[19].Inshort,fourpathologic
parameters were scored on a scale of 0–4: (a) alveolar
congestion, (b) hemorrhage, (c) leukocyte inﬁltration, and
(d) thickness of alveolar wall/hyaline membranes. A score of
0 represents normal lungs; 1, mild, <25% lung involvement;
2, moderate, 25–50% lung involvement; 3, severe, 50–75%
lung involvement; 4, very severe, >75% lung involvement.
The total histology score was expressed as the sum of the
score for all parameters.
2.7. Assays. Cytokine and chemokine levels in the BALF
were measured by enzyme-linked immunosorbent assay
(ELISA) according to the manufacturer’s instructions. Inter-
leukin (IL)-6, macrophage inﬂammatory protein (MIP)-2
and keratinocyte-derived chemokine (KC) assays were all
obtained from the R&D Systems (Abingdon, UK).
2.8. Statistical Analysis. All data in the results are expressed
as means ± SEM. To detect diﬀerences between groups, the
Dunnett method was used, in conjunction with two-way
analysis of variance and the Mann Whitney U test. A P value
of <0.05 was considered signiﬁcant. All statistical analyses
were carried out using SPSS 12.0.2 (SPSS, Chicago, IL).
3. Results
3.1.HemodynamicandVentilatoryMonitoring. Allventilated
animals survived the 5 hours of MV. Blood gas analysis
revealed adequate gas exchange as previously shown [14].
Arterial pressure and heart rate remained stable in all
animals throughout the experiment, with no diﬀerences
notedbetweenbeforeandafterinfusion, norbetweengroups
(data not shown).
3.2. Eﬀect of Mechanical Ventilation with High Tidal Vol-
ume. Animals receiving high tidal MV showed pulmonary
neutrophil sequestration with an increased wet-to-dry ratio
of the lungs and increased pulmonary protein leakage
compared to animals receiving low tidal MV (Figures 1 and
2, P<0.01), consistent with previous results [14, 18, 20].
Also, high tidal MV resulted in increased pulmonary levels
of KC and IL-6 compared to low tidal MV (Figures 3(a) and
3(b), P<0.01).
3.3. Eﬀect of MHC-I Antibody Infusion in Mice Ventilated
with Injurious Tidal Volumes. The increased wet-to-dry
ratio of the lungs induced by high tidal MV was further
increased after infusion with a high dose of MHC-I anti-
bodies (4.5mg/kg) compared to animals receiving vehicle
(Figure 1(b), P<0.01). Animals ventilated with high
tidal MV and receiving high dose of MHC-I antibodies
had increased neutrophil inﬂux in the BALF and increased
pulmonary levels of KC compared to animals receiving
vehicle (Figures 1(c) and Figure 3, P<0.05 and P<0.01,
resp.). This eﬀect was also seen for pulmonary levels of IL-
6 and MIP-2, although not reaching statistical signiﬁcance
(Figures 3(b) and 3(c), ns). No diﬀerence was seen in
total protein leakage in the BALF between animals receiving
MHC-I antibodies and controls (Figure 1(a),n s ) .I na n i m a l s
ventilated with injurious ventilator settings, a low dose
(0.5mg/kg) of MHC-I antibodies induced a nonsigniﬁcant
trend for pulmonary neutrophil sequestration, increase of
pulmonary levels of KC, and increase in lung injury score
compared to animals receiving vehicle (Figures 1, 2,a n d3).
3.4. Eﬀect of MHC-I Antibody Infusion in Mice Ventilated
with Protective Tidal Volumes. In animals ventilated with
low tidal volume, infusion of MHC-I antibodies did not
increase wet-to-dry ratio or neutrophil inﬂux, irrespective
of the concentration used (Figure 1). Infusion of high
dose (4.5mg/kg) MHC-I antibodies in animals ventilated
with protective ventilator settings resulted in an increase
in total protein leakage in the BALF, lung injury score
and pulmonary KC, and IL-6 levels compared to animals
receiving vehicle (Figures 1 and 3).
4. Discussion
Here, we describe the eﬀect of diﬀerent doses of antibod-
ies in inducing TRALI in a clinically relevant model of
mechanically ventilated animals. We hypothesized that in,
the presence of injurious MV (“ﬁrst hit”), lower titers of
antibodies would result in aggravation of lung injury, which
would not occur in the presence of “protective” MV. We
found evidence for a titer threshold in the induction of
TRALI for some lung injury parameters, suggesting that
onset of TRALI depends both on the “ﬁrst hit” as well as
on the amount of MHC-I antibodies infused. However, this
eﬀect was not ubiquitous for all parameters of lung injury.
Also, we found that already low concentrations of MHC-I
antibodies can induce lung injury, even in the presence of
a“ p r o t e c t i v e ”M Vs t r a t e g y .
Originally, TRALI was thought to be a “single hit”
antibody-mediated reaction, in which antibodies in the
blood product react with a matching antigen in the recipient,
leading to pulmonary edema [21]. Then, evidence emerged
that host factors play an important role in determining
whether or not a TRALI reaction occurs [9, 11, 12]. The
concept that the presence of a “ﬁrst hit” may be required for4 Critical Care Research and Practice
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Figure 1: (a) Total protein in the bronchoalveolar lavage ﬂuid (BALF) (n = 12 per group), (b) wet-to-dry ratio of the lungs (n = 6p e r
group), (c) neutrophil inﬂux in bronchoalveolar lavage ﬂuid (n = 12 per group), and (d) histopathological examination of lung tissue
(n = 6 per group). Low VT = mice ventilated with a tidal volume of 7.5mL/kg; high VT = mice ventilated with a tidal volume of 15mL/kg.
Dose of MHC-I antibodies infused 0.5, 2.0, and 4.5mg/kg. Controls received vehicle. BALF = bronchoalveolar lavage ﬂuid. ∗P<0.05,
∗∗P<0.01.
a TRALI reaction has been shown in several non-immune-
mediated TRALI models. Infusion of stored blood products
or bioactive lipids requires LPS priming before inducing
aT R A L Ir e a c t i o n[ 22–26]. Recent studies show that the
“two-event model” also holds true for immune-mediated
TRALI using LPS as a “ﬁrst hit” [13, 22]. Here, we conﬁrm
the ﬁnding of a threshold dependency with a clinically
relevant “ﬁrst hit” of injurious MV for some parameters of
TRALI, the most apparent being the increase in pulmonary
edema, an eﬀect that was not observed after infusion of
lower concentrations of MHC-I antibodies. However, not
all parameters of lung injury showed a similar threshold,
including protein leakage. An explanation for this ﬁnding
may be that injurious MV already elicits protein leakage
[18], as also seen in this study, which could not be further
enhanced by MHC-I antibodies.
Our ﬁndings may suggest that mechanically ventilated
patients may be at risk for the onset of TRALI. This accords
with the ﬁnding that mechanically ventilated critically ill
patients are at risk for onset of ALI after transfusion with
fresh frozen plasma [27]. The mechanism of the synergistic
eﬀect of injurious MV and TRALI [14]m a yb er e c r u i t m e n t
of neutrophils to the pulmonary compartment induced by
MV [28], resulting in a proinﬂammatory response (i.e.,
priming), resembling a “ﬁrst hit” in TRALI models. The
primed pulmonary neutrophils may be prone to activation
after a “second hit,” which results in TRALI. In the absence
of the primed neutrophils (i.e., “ﬁrst hit”), the “secondCritical Care Research and Practice 5
(a) (b) (c)
(d) (e) (f)
(g) (h)
Figure 2: Histologic sections of hematoxylin-and-eosin-stained mice lungs at 100x magniﬁcation after mechanical ventilated using low
ventilation tidal (VT) (7.5mL/kg) or high VT (15mL/kg). Ventilated animals receiving 0.5mg/kg, 2.0mg/kg or 4.5mg/kg MHC-I antibody
(n = 6 per group). (a) low VT control, (b) high VT control, (c) 0.5mg/kg low VT, (d) 0.5mg/kg high VT, (e) 2.0mg/kg low VT, (f) 2.0mg/kg
high VT, (g) 4.5mg/kg low VT, (h) 4.5mg/kg high VT. Neutrophils sequestrated in the vasculature (arrow; (a)–(h)). Increased pulmonary
edema and neutrophil extravasation ((d), (f)–(h)).
hit” may not overcome the threshold and TRALI will not
occur [22]. In support of this view, resting neutrophils
e x p r e s sH L Ac l a s sI Ia n t i g e n sa tv e r yl o wl e v e l s ,w h e r e a s
cytokine-activated neutrophils express increased HLA class
II antigens [29, 30]. In line with the thought that MV may
serve as a predisposing clinical condition in the onset of
TRALI, we found that lung injury score worsened already
after infusion of the lowest dose of MHC-I antibodies,
irrespective of the ventilation strategy. Although it is not
apparent from this study whether MV can prime pulmonary
neutrophils, thereby increasing susceptibility for a TRALI
reaction, we conclude that already low dose of MHC-I
antibodieselicitspulmonaryinﬂammationinthepresenceof
MV. Whether or not MV may account for the high incidence
of TRALI among the critically ill remains to be determined
[9–11].
The ﬁnding that injurious MV settings can facilitate
the onset and course of a TRALI reaction, allowing for
a lower titer of MHC-I antibodies to induce TRALI, may
have relevance for the prevention of TRALI. Recent clin-
ical data indicate that the volume of cognate antibodies
transfused is indeed a risk factor for TRALI [31]. Plasma
volumes in red blood cell units as small as 10–20mL or
a single buﬀy coat donor from a pooled platelet product
was reported suﬃcient to cause TRALI [32]. Plasma from
multiparous donors contains higher levels of leukocyte
and/or neutrophil antibodies due to sensitization during
labour compared to male donors. Excluding female donors
for high-volume plasma components in the UK and The
Netherlands reduced the onset of TRALI in surgical and
critically ill patient populations [33–35]. However, defer-
ring women from plasma donation has a strong impact
on blood supply. Further research is needed to establish
which titer of antibodies can be safely transfused and
whether this concentration threshold diﬀers between rela-
tively healthy recipients and mechanically ventilated patients6 Critical Care Research and Practice
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Figure 3: (a) Keratinocyte-derived chemokine (KC) (n = 12 per group), (b) interleukin (IL)-6 (n = 6 per group) and (c) MIP-2
concentrations(n = 6pergroup)inthebronchoalveolarlavageﬂuid(BALF).Ventilatedanimalsreceiving0.5mg/kg,2.0mg/kg,or4.5mg/kg
MHC-Iantibody.AnimalswerelowVT (tidalof7.5mL/kg)andhighVT (tidalof15mL/kg).Controlsreceivedvehicle. ∗P<0.05, ∗∗P<0.01.
undergoing surgery or suﬀering from an inﬂammatory
condition.
There are limitations to this study which hamper the
relevance of our ﬁndings for clinical practice. Obviously,
results of an animal model cannot be translated directly
to the clinical setting. We do not know whether 4.5mg/kg
MHC-I is a clinical relevant dose. Also, we infused a
component of the blood product which does not reﬂect the
clinical situation. Although MHC-I antibody is the main
cause of antibody mediated TRALI, we cannot rule out that
other blood components may play a role in the onset of lung
injury. Results may, however, serve to explore the hypothesis
that mechanically ventilated patients beneﬁt from a policy of
plasma with a reduced titer of antibodies.
5. Conclusion
InthepresenceofinjuriousMV,onsetofTRALIisdependent
on the amount of MHC-I antibodies infused, supporting
the threshold model. Results may suggest that decreasing the
concentration of antibodies in blood products may lower the
risk of a TRALI reaction in mechanically ventilated patients.
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